More than 1.5 million families and over 155 hospitals nationwide had benefited from the P120 million monetary and in-kind donations to the country’s COVID-19 from the Pharmaceutical and Healthcare Association of the Philippines.
As part of their corporate social responsibility, trusted medicines and vaccines providers belonging to PHAP are also volunteering in community efforts to support frontline health workers and patients impacted by the COVID-19 outbreak.
In-kind donations of PHAP members consist of Personal Protective Equipment sets (coveralls, N95 masks, surgical masks, surgical gloves, face shields, goggles, shoe covers), test kits, ventilators, medicines, vitamins, vaccines, personal hygiene items, disinfectants, food packs for frontline health workers, and transportation assistance for patients. Beneficiaries include government and private hospitals, charitable institutions, government agencies, and nongovernmental organizations (NGOs), among others.
“Even as the global biopharmaceutical industry is leading the way in developing COVID- 19 vaccines, treatments and diagnostics, we are taking concrete actions to support the Philippine government’s COVID-19 response,” said PHAP Executive Director Teodoro Padilla.
“We are working round the clock to ensure an uninterrupted supply of life-saving medicines despite global lockdowns. Also a key component of these actions is our corporate social responsibility initiatives aimed at protecting frontline health workers and patients,” he added.
Aside from their respective company’s COVID-19 response initiatives, PHAP members also contributed a total of P8.5 million monetary and in-kind donations to the PHAPCaresFoundation, the social responsibility arm of PHAP dedicated to help improve the health and lives of Filipinos disadvantaged by sickness, poverty and disasters.
“As responsible corporate citizens, PHAP and its member companies are committed to support the country’s health care system capacity and protect health care workers and patients. We are one with the government and all concerned stakeholders in the fight against COVID-19,” said PHAPCares Foundation Executive Director Dr. Rosarita Quijano-Siasoco.
The PHAP Members that have so far contributed to the country’s COVID-19 response are Abbott Laboratories Philippines; Astellas; AstraZeneca Pharmaceuticals (Phils.) Inc.; Bayer Philippines, Inc.; Boehringer Ingelheim (Philippines), Inc.; GlaxoSmithKline )GSK) Philippines Inc.; Hi-Eisai Pharmaceutical, Inc. (Philippines); Johnson & Johnson; Merck Group, Inc.; MSD Philippines; Mercury Drug Corporation; Metro Drug Inc.; Mundipharma Distribution GmbH (Philippine Branch); Novartis Healthcare Philippines, Inc.; Novo Nordisk; Otsuka (Philippines) Pharmaceutical, Inc.; Pfizer Philippines, Inc.
